BOT - Anything but charting, page-10396

I am surprised by the book published on Sofdra ...early Drugs.com very positive reviews ...pricing usd 1 200..

Net Revenue can be higher, not usd500 but usd 700 or 800...This is minor detail now


FDA protection offers 15-20 years on novel drugs and with some formula mix down the road it can be extended ( most drug companies do it) - not a worry at all at this stage

all indicates that the door is opening..

1% penetration- aud 2 per share just on 6 prescriptions per year

Matt said any leading novel drug should get 30% market ..

Even if he 3x wrong..we still can stare at 10% of market penetration